Event
FDA approves oral orforglipron (Foundayo)
Global · Regulatory
What to watch
Why variis flagged this
The first oral GLP-1 receptor agonist to clear the FDA.
Common questions
- FDA approves oral orforglipron (Foundayo): what happened?
- The first oral GLP-1 receptor agonist to clear the FDA.
- FDA approves oral orforglipron (Foundayo): when?
- 1 April 2026. variis records dates only to the precision the source published, so a date given here as a month or a year is not being rounded from something more exact.
- FDA approves oral orforglipron (Foundayo): who is involved?
- Eli Lilly
- FDA approves oral orforglipron (Foundayo): why does variis track it?
- It is recorded as regulatory, one of the categories variis follows across the longevity market.
Keep reading
Related coverage from the newsroom.
Every entity profile on variis is sourced. Not medical or investment advice.